• Wenbiao Han, Jing Zhang, Tao Song, and Yanni Han.
• Wenbiao Han, Department of Endocrinology, Qingyang people's Hospital, Qingyang 745000, Gansu Province, P.R. China.
• Pak J Med Sci. 2022 Sep 1; 38 (7): 2016-2020.

ObjectiveTo explore the significance of recombinant human growth hormone(rhGH) therapy in promoting the growth and development of children with idiopathic short stature (ISS).MethodsMedical records of 95 children with ISS, treated in our hospital from July 2019 to July 2020, were retrospectively selected and divided into two groups based on the received treatment. Of them, 41 patients received routine treatment (Group-I) and 54 patients received a combination of routine and rhGH treatment (Group-II). The levels of serum insulin-like growth factor-1 (IGF-1), bone age, growth velocity, height standard deviation score (Ht-SDS), and adverse reactions were compared and analyzed between the two groups.ResultsAfter treatment, IGF-1, bone age, growth velocity, and Ht-SDS in Group-II were higher than those in Group-I (P < 0.05); After treatment, the incidence of adverse reactions in Group-II was 7.41%, which had no significant difference compared with 7.32% in Group-I (P > 0.05).ConclusionIn the treatment of children with Idiopathic Short Stature (ISS), the choice of rhGH can further improve the curative effect, promote the growth and development of children, without significant adverse reactions.Copyright: © Pakistan Journal of Medical Sciences.

1 keywords...

hide…